NSE · AHCL · Chemicals
Anlon Healthcare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹31 Cr with net profit ₹5 Cr — a 15.49% net margin, versus 16.56% the period before.
Shareholding
As of 2026-06-30
- Promoter52.68%
- Public44.43%
- FII1.67%
- DII1.22%
34,671 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.82× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Chemicals · ranked #67 of 159 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Solar Industries India Ltd. | ₹2,02,426 Cr | 101.65 | 32.28 | 26.72% | 17.54% |
| Pidilite Industries Ltd. | ₹1,59,705 Cr | 60.3 | 14.74 | 22.61% | 17.2% |
| SRF Ltd. | ₹74,669 Cr | 33.32 | 5.29 | 13.07% | 13.01% |
| Linde India Limited | ₹53,111 Cr | 97.2 | 12.45 | 12.87% | 20.59% |
| Gujarat Fluorochemicals Ltd. | ₹52,578 Cr | 85.12 | 6.76 | 7.13% | 11.41% |
| Navin Fluorine International Ltd. | ₹44,646 Cr | 56.14 | 11.23 | 16.69% | 21.73% |
| Godrej Industries Ltd. | ₹37,805 Cr | 30.9 | 3.39 | 11.1% | 5.06% |
| Himadri Speciality Chem Limited | ₹33,491 Cr | 41.9 | 7.12 | 15.96% | 16.07% |
| Deepak Nitrite Ltd. | ₹22,448 Cr | 28.34 | 3.85 | 9.43% | 9.13% |
| Aether Industries Limited | ₹21,771 Cr | 90.72 | 8.88 | 8.94% | 19.11% |
| Anlon Healthcare Limited(this company) | ₹932 Cr | 29.23 | 4.05 | 12.39% | 13.98% |
AI analysis
AI-generated · google/gemini-2.5-flashAnlon Healthcare Limited (AHCL) is listed in the Chemicals sector with a market capitalization of Rs 817 Cr. The company reported an EPS of 0.54 and a PE ratio of 28.46. Its book value stands at 4.33, with a Return on Equity (ROE) of 12.39% and a Return on Capital Employed (ROCE) of 16.89%. The debt-to-equity ratio is 1.46. For the quarter ended March 2026, the company recorded revenue of Rs 50.89 Cr and a net profit of Rs 10.5 Cr.
Positives
- +The Return on Capital Employed (ROCE) was 16.89%, indicating efficient use of capital.
- +Promoter shareholding in March 2026 was 52.68%, representing a majority stake.
- +No shares were pledged by promoters, with promoter pledge at 0%.
Negatives
- −The profit margin is 0%, indicating no profitability from operations based on the provided figure.
- −The debt-to-equity ratio is 1.46, which is relatively high.
- −Promoter shareholding significantly decreased from 70.26% in October 2024 to 52.68% in March 2026.
- −The company reported a negative net profit of Rs -2.49 Cr in December 2024.
- −No dividend yield was reported (0%).
Financial Performance
In the financial year ending March 2025, Anlon Healthcare Limited reported total revenue of Rs 120.45 Cr and a net profit of Rs 20.52 Cr. Quarterly revenue for March 2026 was Rs 50.89 Cr, with a net profit of Rs 10.5 Cr. This follows a previous quarter in December 2025 where revenue was Rs 35.58 Cr and net profit was Rs 5.15 Cr.
Profitability & Returns
The company's Return on Equity (ROE) is 12.39%, while the Return on Capital Employed (ROCE) is 16.89%. The earnings per share (EPS) for the most recent available annual period (Mar 2025) was Rs 6.37. The profit margin for the company is 0% based on the provided data.
Balance Sheet
Anlon Healthcare Limited has a debt-to-equity ratio of 1.46, indicating a significant reliance on debt financing. The book value per share is Rs 4.33. No further detailed balance sheet figures are available in the provided data.
Ownership & Pledges
Public shareholding stands at 42.40%. Total institutional holding is 4.92%. There are no promoter shares pledged, with promoter pledge at 0%.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.